What question did this study set out to answer?

This research aims to assess the safety and effectiveness of extended intravenous tenecteplase thrombolysis for distal medium vessel occlusion stroke within 4.5–24 hours of symptom onset.

April 15, 2026Stroke and Vascular NeurologyOpen Access

Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale

View Full Paper

Ask AI

Bookmark

This research aims to assess the safety and effectiveness of extended intravenous tenecteplase thrombolysis for distal medium vessel occlusion stroke within 4.5–24 hours of symptom onset.
Prospective, randomised controlled multicentre open-label design
Up to 560 subjects randomised 1:1 to receive either TNK thrombolysis or standard medical management
Conducted across over 40 comprehensive stroke centres in China
Blinded outcome assessment of efficacy and safety endpoints
Primary outcome measured by modified Rankin Scale score of 0–1 at 90 days
Safety measures include rates of symptomatic intracerebral haemorrhage within 24 hours and mortality at 90 days

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Prospective trial investigates the effects of extended TNK thrombolysis in MeVO stroke, indicating potential treatment advantages.

Cite This Study

Jing et al. (2026) studied this question.

synapsesocial.com/papers/69df2b49e4eeef8a2a6b041e https://doi.org/10.1136/svn-2025-004727

View Full Paper

Ask AI

Bookmark

Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale

Key Points

Discussion

Implication

Cite This Study

Extending the time window for intravenous tenecteplase in patients with distal medium vessel occlusions stroke: study protocol and rationale

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider